HC Wainwright Has Bearish Forecast for Brainsway Q3 Earnings

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Equities research analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for Brainsway in a report issued on Monday, August 31st. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.12 for the quarter, down from their previous estimate of $0.13. HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for Brainsway’s current full-year earnings is $0.34 per share. HC Wainwright also issued estimates for Brainsway’s Q2 2027 earnings at $0.18 EPS, Q3 2027 earnings at $0.20 EPS, Q4 2027 earnings at $0.22 EPS and FY2027 earnings at $0.75 EPS.

BWAY has been the topic of several other reports. LADENBURG THALM/SH SH raised their price objective on Brainsway from $18.00 to $18.80 and gave the stock a “buy” rating in a report on Thursday, August 13th. New Street Research restated a “buy” rating on shares of Brainsway in a research note on Friday, July 24th. Weiss Ratings downgraded Brainsway from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, August 19th. BTIG Research raised their target price on shares of Brainsway from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Finally, Zacks Research cut shares of Brainsway from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Brainsway has a consensus rating of “Moderate Buy” and a consensus price target of $18.20.

Brainsway Stock Performance

Shares of NASDAQ:BWAY opened at $14.52 on Tuesday. The firm’s 50 day simple moving average is $15.21 and its 200-day simple moving average is $14.63. Brainsway has a one year low of $7.14 and a one year high of $17.40. The firm has a market cap of $583.56 million, a PE ratio of 33.00 and a beta of 1.24.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.10 by $0.04. The company had revenue of $17.11 million for the quarter, compared to the consensus estimate of $16.54 million. Brainsway had a net margin of 15.65% and a return on equity of 12.74%.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Ballast Advisors LLC purchased a new stake in Brainsway during the first quarter valued at approximately $55,000. Bank of America Corp DE purchased a new position in Brainsway in the first quarter worth $206,000. Royal Bank of Canada increased its position in shares of Brainsway by 84.2% during the first quarter. Royal Bank of Canada now owns 15,490 shares of the company’s stock worth $206,000 after purchasing an additional 7,080 shares in the last quarter. Masters Capital Management LLC lifted its holdings in shares of Brainsway by 65.0% during the 1st quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock valued at $21,928,000 after purchasing an additional 650,000 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Brainsway by 87.2% during the 1st quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock valued at $6,890,000 after purchasing an additional 241,560 shares during the last quarter. Institutional investors own 30.11% of the company’s stock.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.